Vaccinex Total Assets 2017-2021 | VCNX

Vaccinex total assets from 2017 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Vaccinex Annual Total Assets
(Millions of US $)
2020 $12
2019 $5
2018 $22
2017 $6
2016 $3
Vaccinex Quarterly Total Assets
(Millions of US $)
2021-09-30 $15
2021-06-30 $24
2021-03-31 $31
2020-12-31 $12
2020-09-30 $19
2020-06-30 $3
2020-03-31 $5
2019-12-31 $5
2019-09-30 $11
2019-06-30 $7
2019-03-31 $13
2018-12-31 $22
2018-09-30 $30
2018-06-30 $5
2018-03-31 $5
2017-12-31 $6
2017-09-30 $0
2017-06-30 $0
2017-03-31 $0
2016-12-31 $3
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.046B $0.001B
Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company's product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $121.969B 7.71
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.359B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $7.214B 0.00
Arcus Biosciences (RCUS) United States $3.030B 0.00
Emergent Biosolutions (EBS) United States $2.347B 8.44
ADC Therapeutics SA (ADCT) Switzerland $1.505B 0.00
Myovant Sciences (MYOV) United Kingdom $1.429B 0.00
Zymeworks (ZYME) Canada $0.942B 0.00
Ambrx Biopharma (AMAM) United States $0.366B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09